Back to Search Start Over

Methylation Analyses Reveal Promoter Hypermethylation as a Rare Cause of "Second Hit" in Germline BRCA1-Associated Pancreatic Ductal Adenocarcinoma.

Authors :
Zheng-Lin B
Rainone M
Varghese AM
Yu KH
Park W
Berger M
Mehine M
Chou J
Capanu M
Mandelker D
Stadler ZK
Birsoy O
Jairam S
Yang C
Li Y
Wong D
Benhamida JK
Ladanyi M
Zhang L
O'Reilly EM
Source :
Molecular diagnosis & therapy [Mol Diagn Ther] 2022 Nov; Vol. 26 (6), pp. 645-653. Date of Electronic Publication: 2022 Sep 30.
Publication Year :
2022

Abstract

Background and Objective: Pancreatic ductal adenocarcinoma (PDAC) is characterized by the occurrence of pathogenic variants in BRCA1/2 in 5-6% of patients. Biallelic loss of BRCA1/2 enriches for response to platinum agents and poly (ADP-ribose) polymerase 1 inhibitors. There is a dearth of evidence on the mechanism of inactivation of the wild-type BRCA1 allele in PDAC tumors with a germline BRCA1 (gBRCA1) pathogenic or likely pathogenic variant (P/LPV). Herein, we examine promotor hypermethylation as a "second hit" mechanism in patients with gBRCA1-PDAC.<br />Methods: We evaluated patients with PDAC who underwent Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) somatic and germline testing from an institutional database. DNA isolated from tumor tissue and matched normal peripheral blood were sequenced by MSK-IMPACT. In patients with gBRCA1-PDAC, we examined the somatic BRCA1 mutation status and promotor methylation status of the tumor BRCA1 allele via a methylation array analysis. In patients with sufficient remaining DNA, a second methylation analysis by pyrosequencing was performed.<br />Results: Of 1012 patients with PDAC, 19 (1.9%) were identified to harbor a gBRCA1 P/LPV. Fifteen patients underwent a methylation array and the mean percentage of BRCA1 promotor methylation was 3.62%. In seven patients in whom sufficient DNA was available, subsequent pyrosequencing confirmed an unmethylated BRCA1 promotor. Loss of heterozygosity was detected in 12 of 19 (63%, 95% confidence interval 38-84) patients, demonstrating loss of heterozygosity is the major molecular mechanism of BRCA1 inactivation in PDAC. Two (10.5%) cases had a somatic BRCA1 mutation.<br />Conclusions: In patients with gBRCA1-P/LPV-PDAC, loss of heterozygosity is the main inactivating mechanism of the wild-type BRCA1 allele in the tumor, and methylation of the BRCA1 promoter is a distinctly uncommon occurrence.<br /> (© 2022. The Author(s).)

Details

Language :
English
ISSN :
1179-2000
Volume :
26
Issue :
6
Database :
MEDLINE
Journal :
Molecular diagnosis & therapy
Publication Type :
Academic Journal
Accession number :
36178671
Full Text :
https://doi.org/10.1007/s40291-022-00614-1